Aktieanalys

Xbrane Biopharma: Ximluci Approved in the EU - Redeye

{newsItem.title}

Redeye Publicerad: 11 Nov 2022 09:54

Xbrane Biopharma

Redeye leaves a short comment on today’s news that Xbrane and STADA have secured EU approval for Ximluci. Today’s announcement was expected, but it nevertheless marks a significant milestone for the company, and the Q1 2023 launch is nearing swiftly.

Länk till analysen i sin helhet: https://www.redeye.se/research/862858/xbrane-biopharma-ximluci-approved-in-the-eu?utm_source=finwire&utm_medium=RSS

Nyheter om Xbrane Biopharma

Läses av andra just nu

Om aktien Xbrane Biopharma

Senaste nytt